1. Home
  2. CHRN vs HRMY Comparison

CHRN vs HRMY Comparison

Compare CHRN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ChronoScale Corporation Common Stock

CHRN

ChronoScale Corporation Common Stock

N/A

Current Price

$20.06

Market Cap

2.9B

Sector

Industrials

ML Signal

N/A

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$39.98

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CHRN
HRMY
Founded
N/A
2017
Country
United States
United States
Employees
88
293
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.4B
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
CHRN
HRMY
Price
$20.06
$39.98
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
★ $44.11
AVG Volume (30 Days)
115.1K
★ 866.4K
Earning Date
N/A
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 92.67
7.97
EPS
N/A
★ 1.84
Revenue
N/A
★ $868,453,000.00
Revenue This Year
N/A
$19.75
Revenue Next Year
N/A
$12.88
P/E Ratio
★ N/A
$22.46
Revenue Growth
N/A
★ 21.51
52 Week Low
$15.74
$25.52
52 Week High
$30.00
$43.49

Technical Indicators

Market Signals
Indicator
CHRN
HRMY
Relative Strength Index (RSI) 46.08 44.35
Support Level $18.93 $37.30
Resistance Level $22.00 $43.38
Average True Range (ATR) 1.61 1.21
MACD 0.17 -0.35
Stochastic Oscillator 32.55 2.11

Price Performance

Historical Comparison
CHRN
HRMY

About CHRN ChronoScale Corporation Common Stock

ChronoScale Holdings Corp is providing cloud services to customers at third-party colocation centers located in Colorado, Minnesota and Utah, such as artificial intelligence and machine learning developers, seeking to develop their products. It design, develop, and market exoskeleton and complementary products that augment human strength, endurance, and mobility. Its Cloud Business provides graphics processing unit (GPU) computing solutions that enable customers to execute critical workloads related to artificial intelligence (AI), machine learning (ML), rendering, and other High Performance Computing (HPC) tasks at scale in a capacity-constrained market. It has one operating segment Cloud Business.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: